跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Selective Killing: How Chemotherapy Harms Cancer Cells More Than Normal Cells

1The Selectivity Problem: Why Preferential Killing Is Possible but Imperfect2Proliferation as the Primary Vulnerability: Cell-Cycle Dependence3Antimetabolites and the S-Phase Trap4Microtubule Poisons and Mitotic Arrest5DNA-Damaging Agents: Alkylators, Crosslinkers, and Topoisomerase Poisons6The DNA-Damage Response and the Decision to Die7Why Selectivity Fails: Normal-Tissue Toxicity and the Limits of the Window8Resistance: How Tumors Escape and What It Reveals About Selectivity9Widening the Window: Clinical Strategies That Exploit Selectivity
The DNA-Damage Response and the Decision to Die

Why p53 Loss Makes DNA-Damaging Drugs Less Effective

3 / 3
Think about what p53 was doing on the previous two pages. It transcribed p21 to arrest the cell, and it transcribed PUMA and NOXA to trigger apoptosis. Remove p53 and both outputs vanish. The drug still forms the double-strand break — the lesion is there — but the cell no longer stops and no longer dies. It keeps dividing with damaged DNA. That is the mechanistic meaning of p53-associated chemoresistance: the failure is in the interpretation step, not in drug delivery or lesion formation. But be careful with the conclusion. p53 loss does not eliminate every death pathway, and it can make a tumor more sensitive to a drug that exploits a repair defect. So p53 status tells you which selectivity logic the tumor will respond to, not simply whether it will resist.
0:00 / 0:00

Two outputs, one transcription factor

p53 drives both the arrest arm (via CDKN1A/p21) and the apoptotic arm (via PUMA and NOXA). Losing p53 removes both. The cell keeps cycling with unrepaired breaks instead of pausing to repair or dying.

Resistance is a failure of interpretation, not of delivery

The drug still forms the lesion. What is missing is the pathway that reads the lesion and converts it into arrest or death. That is why p53-mutant tumors are often less responsive to alkylators, platinum agents, and topoisomerase poisons.

Two qualifications

p53 loss does not abolish all apoptosis — p53-independent death pathways exist. And p53 loss can make a tumor more sensitive to agents that exploit a repair defect, which is the basis of synthetic lethality. p53 status predicts which selectivity logic applies, not simply whether the tumor is resistant.

参考资料

  1. [1]p53 mutations in cancerpubmed.ncbi.nlm.nih.gov
上一页3 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion